top of page

How Indian Pharma SMEs Can Go Global in 2025


Pharma SMEs

Indian pharmaceutical Small and Medium Enterprises (SMEs) are well-positioned to expand their reach globally in 2025, thanks to their strong manufacturing capabilities, cost-effective production, and a rich pool of expertise in generic medicines. However, to capitalize on the increasing demand for affordable, high-quality medicines and healthcare solutions worldwide, Indian Pharma SMEs need to adopt a strategic, market-driven approach. Below are key strategies for Indian Pharma SMEs to go global in 2025:


1. Leverage India’s Regulatory Strengths for International Market Access

India has become a hub for high-quality, cost-effective pharmaceutical manufacturing due to its adherence to global regulatory standards, such as Good Manufacturing Practices (GMP), WHO-GMP, and USFDA. Indian SMEs can utilize this:


  • Obtain international certifications for quality (e.g., EU-GMP, USFDA, TGA, etc.) to enhance market credibility.

  • Expand into regulated markets like the USA, EU, Japan, and Australia, where there is a high demand for affordable generics.

Example: Several Indian SMEs have successfully entered the US market by obtaining USFDA approval for generic formulations, offering affordable alternatives to high-cost branded medicines.

2. Focus on Niche and High-Demand Therapeutic Areas

Indian Pharma SMEs can differentiate themselves in the global market by focusing on niche therapeutic areas or those with a high unmet need. Some lucrative areas include:


  • Chronic diseases: Diabetes, cardiovascular diseases, oncology

  • Biologics and biosimilars: Developing cost-effective alternatives to biologic drugs

  • Specialty generics: Rare disease treatments or high-value generics

  • Herbal and nutraceuticals: Leveraging India’s traditional medicine knowledge, such as Ayurvedic and Herbal formulations.


By aligning their offerings with global healthcare trends, Indian SMEs can fill gaps in the market and gain a competitive edge.

Example: Indian companies like Biocon and Cipla have tapped into the biosimilars market, which has substantial growth potential in global markets.

3. Invest in R&D and Innovation

SMEs can build long-term competitiveness by investing in Research and Development (R&D) and innovation to develop new drug formulations or improve the bioavailability of existing molecules. Global markets, especially in developed regions, prioritize:


  • Innovative drug delivery systems

  • Customized formulations (e.g., pediatric dosage forms, controlled release)

  • Patent filing and IP protection


Indian Pharma SMEs can partner with international R&D labs, universities, or contract research organizations (CROs) to boost innovation and speed up the time-to-market for new products.

Example: R&D-driven growth has enabled companies like Dr. Reddy’s to enter high-value global markets with new drug launches and value-added formulations.

4. Strengthen Distribution Networks and Partnerships

Global expansion requires a robust distribution network. Indian Pharma SMEs should:

  • Form strategic partnerships with global distributors, wholesalers, and retailers.

  • Consider contract manufacturing agreements with international pharma companies to expand market reach without the need for massive capital investment in infrastructure.

  • Participate in global pharma trade shows, conferences, and industry events to network with potential partners.

Example: Indian pharma companies often enter international markets by forming joint ventures or partnerships with companies in the Middle East, Africa, and Southeast Asia.

5. Embrace Digitalization and E-Commerce for Global Reach

With the growth of digital transformation and e-commerce, Indian Pharma SMEs can gain access to global markets at a fraction of the cost traditionally required. The benefits include:


  • Online pharma platforms for direct-to-consumer sales, especially for nutraceuticals, over-the-counter (OTC) drugs, and health supplements.

  • Telemedicine and e-pharmacy collaborations, especially in Southeast Asia, Africa, and the Middle East, where e-pharmacy is gaining popularity.

  • Digital marketing, including social media presence, to reach international customers and healthcare professionals.

Example: Companies like Healthkart and PharmEasy are examples of successful e-commerce platforms that allow pharmaceutical SMEs to sell overseas with minimal setup.

6. Navigate Intellectual Property (IP) and Patent Challenges

Indian Pharma SMEs must be proactive in managing intellectual property (IP), especially when entering global markets. While India’s patent laws allow for generic medicines, SMEs must consider:


  • Patent filing in key international markets to protect innovations.

  • Understanding compulsory licensing and generic drug policies in various regions, particularly in countries with stringent patent regulations.

Example: Indian companies like Natco Pharma and Hetero Drugs have successfully navigated IP challenges to launch generics of patented drugs in the global market.

7. Capitalize on Government Initiatives and Trade Agreements

The Indian government has implemented several supportive initiatives to assist pharma SMEs in going global:


  • Pharma Export Promotion Scheme: This program provides incentives for promoting Indian pharma products in international markets.

  • Productivity Linked Incentive (PLI) Scheme: Supports pharmaceutical manufacturing and innovation in India, offering subsidies and tax incentives.

  • Bilateral trade agreements: India has signed trade agreements with several countries (e.g., RCEP, EU), making market entry easier.


Example: The PLI scheme has helped Indian companies like Aurobindo Pharma expand their manufacturing capabilities and improve their competitive advantage in global markets.

8. Address Global Regulatory Requirements

Global markets, especially the US, Europe, and Japan, have stringent regulatory requirements. Indian Pharma SMEs must:


  • Familiarize themselves with drug approval processes in target markets (e.g., USFDA, EMA, TGA).

  • Ensure compliance with Good Clinical Practices (GCP), Good Laboratory Practices (GLP), and Good Manufacturing Practices (GMP).

  • Invest in regulatory affairs teams to facilitate smooth market entry.


Example: Indian companies like Lupin Pharmaceuticals have achieved regulatory approvals for a wide range of generics in the US market, ensuring they meet FDA requirements.

9. Focus on Export of Ayurvedic and Herbal Products

Indian Pharma SMEs can capitalize on the growing global interest in Ayurvedic and herbal products, especially with increasing consumer awareness around natural health solutions. By ensuring quality and obtaining certifications, SMEs can target international markets that are embracing natural remedies and holistic health.

Example: Indian companies like Patanjali Ayurved and Himalaya have gained success in North America and Europe by offering Ayurvedic wellness and beauty products.

✅ Conclusion: Going Global in 2025


Indian Pharma SMEs have a remarkable opportunity to expand into global markets by leveraging India’s strengths in affordable manufacturing, quality assurance, and innovative product development. By adopting strategies such as compliance with global regulations, tapping into niche therapeutic areas, utilizing government support, and strengthening distribution networks, these SMEs can position themselves as key players in the global pharmaceutical market.

With digitalization and international demand on the rise, 2025 offers a perfect opportunity for Indian Pharma SMEs to embrace global expansion and succeed on the world stage.

Comments

bottom of page